Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection
- PMID: 1676275
- DOI: 10.1097/00002030-199103000-00003
Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection
Abstract
Reclustering and indirect immunofluorescence assays on MT-4 cells [carrying both CD4 and complement receptor type 2 (CR2)] were used to measure neutralizing and enhancing antibodies in sera obtained from HIV-1-infected individuals. Heat-inactivated sera were tested before and after mixing 1:1 with fresh seronegative human serum. Using heated samples, neutralizing antibodies were found in 20 out of 20 and 11 out of 19 serum samples of asymptomatic and symptomatic [AIDS, AIDS-related complex (ARC)] HIV-seropositive patients, respectively. In complement-restored samples, neutralizing activity was found in eight sera of asymptomatic patients and in none of the sera of AIDS and ARC patients; enhancing activity could be detected in four and 12 sera, respectively. A significant positive correlation was observed between the titres of neutralizing antibodies measured in the complement-restored samples and the absolute number of CD4+ lymphocytes. These findings indicate that the appearance of complement-dependent enhancing antibodies coincident with the loss of neutralizing antibodies may indicate a poor prognosis in HIV infection.
Similar articles
-
Neutralizing and enhancing antibodies measured in complement-restored serum samples from HIV-1-infected individuals correlate with immunosuppression and disease.AIDS. 1994 May;8(5):603-9. doi: 10.1097/00002030-199405000-00005. AIDS. 1994. PMID: 7914732
-
Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.AIDS. 1991 May;5(5):513-7. doi: 10.1097/00002030-199105000-00006. AIDS. 1991. PMID: 1863402
-
Complement mediates human immunodeficiency virus type 1 infection of a human T cell line in a CD4- and antibody-independent fashion.J Exp Med. 1991 May 1;173(5):1151-8. doi: 10.1084/jem.173.5.1151. J Exp Med. 1991. PMID: 1827139 Free PMC article.
-
Complement, Fc receptors and antibodies: a Trojan horse in HIV infection?Curr Opin HIV AIDS. 2009 Sep;4(5):394-9. doi: 10.1097/COH.0b013e32832f0108. Curr Opin HIV AIDS. 2009. PMID: 20048703 Review.
-
B cell immunopathology during HIV-1 infection: lessons to learn for HIV-1 vaccine design.Vaccine. 2008 Jun 6;26(24):3016-25. doi: 10.1016/j.vaccine.2007.11.063. Epub 2007 Dec 17. Vaccine. 2008. PMID: 18164520 Review.
Cited by
-
B cell responses to HIV and the development of human monoclonal antibodies.Clin Exp Immunol. 1992 May;88(2):189-202. doi: 10.1111/j.1365-2249.1992.tb03061.x. Clin Exp Immunol. 1992. PMID: 1572084 Free PMC article. Review.
-
Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner.Cell Host Microbe. 2007 Dec 13;2(6):417-26. doi: 10.1016/j.chom.2007.09.015. Cell Host Microbe. 2007. PMID: 18078693 Free PMC article.
-
Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network.J Clin Immunol. 1992 Nov;12(6):429-39. doi: 10.1007/BF00918855. J Clin Immunol. 1992. PMID: 1287035 Clinical Trial.
-
Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41.J Exp Med. 1991 Dec 1;174(6):1557-63. doi: 10.1084/jem.174.6.1557. J Exp Med. 1991. PMID: 1836013 Free PMC article.
-
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Front Immunol. 2017 Nov 28;8:1655. doi: 10.3389/fimmu.2017.01655. eCollection 2017. Front Immunol. 2017. PMID: 29234320 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials